Eyeaze

EyeAze is a UK-based biotechnology company focused on revolutionizing the treatment of chronic eye diseases through non-invasive drug delivery. A spin-out from the University of Birmingham, the company leverages a proprietary cell-penetrating peptide (CPP) platform that enables the delivery of complex drugs to the back of the eye via topical eye drops. This technology aims to eliminate the need for painful and frequent intravitreal injections currently required for conditions like age-related macular degeneration (AMD) and diabetic retinopathy. EyeAze is currently in the pre-clinical stage, working to validate its delivery system for a range of therapeutic payloads. The company's approach has the potential to significantly improve patient adherence and clinical outcomes in the ophthalmology space.